Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

Basit Öğe Kaydı
dc.authoridTürkoğlu, Recai/0000-0001-9724-851X
dc.authorscopusid57195979263
dc.authorscopusid6508110751
dc.authorscopusid23062131200
dc.authorscopusid36708802800
dc.authorscopusid57219650862
dc.authorscopusid6603649950
dc.authorscopusid6602217284
dc.authorwosidTürkoğlu, Recai/B-9336-2014
dc.contributor.authorTuncer, Asli
dc.contributor.authorKurtuncu, Murat
dc.contributor.authorTerzi, Murat
dc.contributor.authorUygunoglu, Ugur
dc.contributor.authorGoncuoglu, Cansu
dc.contributor.authorYuceyar, Ayse Nur
dc.contributor.authorEkmekci, Ozgul
dc.date.accessioned2024-08-25T18:39:05Z
dc.date.available2024-08-25T18:39:05Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs.Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and alter the switch). Data were collected from the MS patients' database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch.Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group.Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.en_US
dc.identifier.doi10.55730/1300-0144.5588
dc.identifier.endpage332en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1en_US
dc.identifier.pmid36945929en_US
dc.identifier.scopus2-s2.0-85149131178en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage323en_US
dc.identifier.trdizinid1160999en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5588
dc.identifier.urihttps://hdl.handle.net/11454/101222
dc.identifier.volume53en_US
dc.identifier.wosWOS:000941667500038en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherScientific And Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectFingolimoden_US
dc.subjectdisease modifying treatmenten_US
dc.subjecttreatment switchen_US
dc.subjectglatiramer acetateen_US
dc.subjectbeta interferonen_US
dc.subjectRemitting Multiple-Sclerosisen_US
dc.subjectNatural-Historyen_US
dc.subjectGlatiramer Acetateen_US
dc.subjectOral Fingolimoden_US
dc.subjectInterferonen_US
dc.subjectEfficacyen_US
dc.titleRetrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu